Panacea Biotec Completes Phase III Enrollment for India's First Indigenous Dengue Vaccine

• Panacea Biotec completed Phase III enrolment for its tetravalent dengue vaccine candidate, DengiAll®.
• 10,335 participants across India enrolled in collaboration with the Indian Council of Medical Research (ICMR).
• Participants will be monitored for two years to evaluate the vaccine's efficacy and immunogenicity.
• DengiAll® aims to be India's first indigenous single-shot dengue vaccine, expected by 2027, pending approvals.
• Panacea Biotec shares closed 4.56% higher on NSE at ₹383 on January 7.

Why It Matters: Panacea Biotec's indigenous dengue vaccine, DengiAll®, moves closer to market with Phase III completion.